Migraine Drugs Market valuation will reach USD 2,971.99 million by the end of 2030

The Global Migraine Drug Market held USD 2,014.14 million in 2019 and is predicted to reach USD 2,971.99 million by 2030 with a CAGR of 3.6% from 2020-2030.

Read Report Overview @

https://www.nextmsc.com/report/migraine-drugs-market

Migraine is a type of headache that is associated with painful headaches and symptoms such as sickness, sensitivity to smell, and others. These headaches commonly occur on one side of the head and can long for various durations with varied intensity. Migraine is the third most widespread and the sixth most disabling illness in the world. For migraine treatment usually prescribed drugs are employed in the treatment process.

Migraines are more common in women as compared to men. The prophylactic and abortive treatments are given for the treating of migraine headache. The increasing number of migraine occurrences and an increasing number of unmet needs in the undeveloped countries will increase the global migraine drugs market size.

The factors including an upsurge in the prevalence of migraine, growth in the female population, and increasing awareness among patients towards migraine treatment & prevention have majorly driven the migraine drugs market. The increased uptake of novel drug classes has further supplemented the market growth. However, the side effects of migraine drugs are hampering the growth of the migraine drugs market. The emerging migraine therapies and growth opportunities in the emerging economies will create new opportunities for market growth in the future.

The migraine drugs market is segmented on the basis of type, administration route, distribution channel, and geography. On the basis of type, the market is segmented into abortive medicine and preventive medicine. The abortive medicine segment is subcategorized into triptans, ergotamine derivative, and others. The preventive medicine segment is subcategorized into antidepressant, beta blocker, anticonvulsant, and others. The administration route segment is further divided oral, injection, and others. On the basis of the distribution channel, the market covers hospital-based pharmacies, retail pharmacies, and online pharmacies. Geographic breakdown and analysis of each of the aforesaid segments include regions comprising North America, Europe, Asia-Pacific, and ROW.

North America held the highest medical drugs market share in the migraine drugs market and is anticipated to hold the highest market size during the forecast period. This is attributable to the factors including technological advancements, adoption of novel therapeutics, the high occurrence of a migraine, and high consumer awareness.

It is expected that the emerging economies, specifically in the Asia-Pacific region would witness increasing market size owing to increasing expenditure on healthcare, low-cost production of drugs, and increasing awareness about diseases.

Request to view Sample Report:

https://www.nextmsc.com/Migraine-Drugs-Market/request-sample

Comprehensive competitive analysis and profiles of the major market players such as Allergan Plc., AstraZeneca, GlaxoSmithKline Plc., Impax Laboratories, Abbott Laboratories, Eisai Co., Ltd., Johnson & Johnson, Merck & Co., Endo International Plc, Pfizer Inc., and others are provided in the migraine drugs market report.